Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (5): 46-51,67.doi: 10.6040/j.issn.1671-7554.0.2021.0262

• Current Advance of Basic and Clinical Medical Virology • Previous Articles     Next Articles

Current progress on prevention of mother to child transmission of hepatitis B virus

Yuchen FAN*()   

  1. Department of Hepatology, Qilu Hospital of Shandong University; Institute of Hepatology, Shandong University, Jinan 250012, Shandong, China
  • Received:2021-03-12 Online:2021-05-10 Published:2021-06-01
  • Contact: Yuchen FAN E-mail:fanyuchen@sdu.edu.cn; pyfanyuchen@126.com

RichHTML

24

PDF (PC)

852

Abstract:

Hepatitis B virus (HBV) infection is a global public threat, which leads to chronic hepatitis B (CHB), liver cirrhosis, liver cancer and liver failure. Mother to child transmission is one of the main ways of HBV transmission. It is of great significance to block the mother to child transmission of HBV through effective intervention to reduce the infection rate of HBV and reduce the burden of HBV related diseases. With the continuous development of China's economy and medical level, measures to prevent mother to child transmission of HBV are constantly improved, which greatly reduces the prevalence of HBV in China. This article summarizes the clinical guidelines and norms for the prevention of mother to child transmission of HBV in China, and summarizes the hot issues and related progress in this field.

Key words: Hepatitis B virus, Interruption of mother to child transmission, Hepatitis B immunoglobulin, Antiviral drugs, Clinical management

CLC Number: 

  • R512.6

Fig.1

Flowchart of HBV mother to child transmission prevention"

1 Liu J , Liang W , Jing W , et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97 (3): 230- 238.
doi: 10.2471/BLT.18.219469
2 Cui F , Shen L , Li L , et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23 (5): 765- 772.
doi: 10.3201/eid2305.161477
3 中华医学会感染病学分会, GRADE中国中心. 中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]. 中华临床感染病杂志, 2019, 37 (7): 388- 396.
4 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华传染病杂志, 2005, 23 (6): 421- 431.
doi: 10.3760/j.issn:1000-6680.2005.06.021
5 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中华肝脏病杂志, 2011, 19 (1): 13- 24.
doi: 10.3760/cma.j.issn.1007-3418.2011.01.007
Chinese Society of Hepatology and Chinese Society of Infectious Diseases , Chinese Medical Association . The guideline of prevention and treatment for chronic hepatitis B (2010 version)[J]. Chinese Journal of Hepatology, 2011, 19 (1): 13- 24.
doi: 10.3760/cma.j.issn.1007-3418.2011.01.007
6 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J]. 中国肝脏病杂志(电子版), 2015, 7 (3): 1- 18.
Chinese Society of Hepatology and Chinese Society of Infectious Diseases , Chinese Medical Association . The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. Chinese Journal of Liver Diseases(Electronic Version), 2015, 7 (3): 1- 18.
7 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27 (12): 938- 961.
doi: 10.3760/cma.j.issn.1007-3418.2019.12.007
Chinese Society of Infectious Diseases Chinese Medical Association; , Chinese Society of Hepatology Chinese Medical Association . The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2019, 27 (12): 938- 961.
doi: 10.3760/cma.j.issn.1007-3418.2019.12.007
8 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020)[J]. 中华妇产科杂志, 2020, 55 (5): 291- 299.
doi: 10.3760/cma.j.cn112141-20200213-00101
9 崔富强, 庄辉. 我国新生儿乙型肝炎母婴阻断成就和展望[J]. 中国病毒病杂志, 2019, 9 (5): 321- 326.
CUI Fuqiang , ZHUANG Hui . Achievements and prospects for preventing mother-to-child transmission of hepatitis B virus in newborns in China[J]. Chinese Journal of Viral Diseases, 2019, 9 (5): 321- 326.
10 贾继东, 侯金林, 魏来, 等. 《慢性乙型肝炎防治指南(2019年版)》新亮点[J]. 中华肝脏病杂志, 2020, 28 (1): 21- 23.
doi: 10.3760/cma.j.issn.1007-3418.2020.01.006
JIA Jidong , HOU Jinlin , WEI Lai , et al. Highlights of guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2020, 28 (1): 21- 23.
doi: 10.3760/cma.j.issn.1007-3418.2020.01.006
11 European Association for the Study of the Liver . EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67 (2): 370- 398.
doi: 10.1016/j.jhep.2017.03.021
12 Terrault NA , Lok ASF , McMahon BJ , et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4): 1560- 1599.
doi: 10.1002/hep.29800
13 周乙华, 李彤, 庄辉. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的商榷[J]. 中华传染病杂志, 2020, 38 (1): 49- 50.
doi: 10.3760/cma.j.issn.1000-6680.2020.01.007
14 徐陈瑜, 陈廷美. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的若干探讨意见[J]. 肝脏, 2020, 25 (3): 228- 230.
doi: 10.3969/j.issn.1008-1704.2020.03.003
15 Mugwanya KK , Hendrix CW , Mugo NR , et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption[J]. PLoS Med, 2016, 13 (9): e1002132.
doi: 10.1371/journal.pmed.1002132
16 Mirochnick M , Taha T , Kreitchmann R , et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life[J]. J Acquir Immune Defic Syndr, 2014, 65 (1): 33- 41.
doi: 10.1097/QAI.0b013e3182a921eb
17 Waitt C , Taha T , Olagunju A , Nakalema S , et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs[J]. J Antimicrob Chemother, 2018, 73 (4): 1013- 1019.
doi: 10.1093/jac/dkx507
18 中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识[J]. 中国病毒病杂志, 2018, 8 (3): 164- 169.
Chinese Society of Hpatology, Chinese Medical Association , et al. Consensus on the management of hepatitis B virus infection in women of childbearing age[J]. Chinese Journal of Viral Diseases, 2018, 8 (3): 164- 169.
19 Sakai K , Ueda A , Hasegawa M , et al. Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review[J]. Int J Hematol, 2018, 108 (2): 203- 207.
doi: 10.1007/s12185-017-2397-8
20 Sandberg-Wollheim M , Alteri E , Moraga MS , et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy[J]. Mult Scler, 2011, 17 (4): 423- 430.
doi: 10.1177/1352458510394610
21 Hiratsuka M , Minakami H , Koshizuka S , et al. Administration of interferon-alpha during pregnancy: effects on fetus[J]. J Perinat Med, 2000, 28 (5): 372- 376.
22 Labarga P , Pinilla J , Cachorro I , et al. Infant of 22 months of age with no anomalies born from a HCV- and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy[J]. Reprod Toxicol, 2007, 24 (3-4): 414- 416.
doi: 10.1016/j.reprotox.2007.07.002
23 Castillo E , Murphy K , van Schalkwyk J . No. 342-hepatitis B and pregnancy[J]. J Obstet Gynaecol Can, 2017, 39 (3): 181- 190.
doi: 10.1016/j.jogc.2016.11.001
24 Wu Y , Liu J , Feng Y , et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis[J]. Hepatol Int, 2020, 14 (2): 180- 189.
doi: 10.1007/s12072-020-10026-0
25 Song J , Yang F , Wang S , et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis[J]. J Viral Hepat, 2019, 26 (3): 397- 406.
26 Zhang H , Pan CQ , Pang Q , et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J]. Hepatology, 2014,
doi: 10.1002/hep.27034
27 Jourdain G , Ngo-Giang-Huong N , Harrison L , et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B[J]. N Engl J Med, 2018, 378 (10): 911- 923.
doi: 10.1056/NEJMoa1708131
28 Pan CQ , Duan Z , Dai E , et al. China study group for the mother-to-child transmission of hepatitis B: tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374 (24): 2324- 2434.
doi: 10.1056/NEJMoa1508660
29 Li J , Chang MS , Tran TT , et al. Management of chronic hepatitis B in pregnancy[J]. J Clin Gastroenterol, 2017, 51 (9): 789- 795.
doi: 10.1097/MCG.0000000000000908
30 Brown Jr RS , McMahon BJ , Lok ASF , et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis[J]. Hepatology, 2016, 63 (1): 319- 333.
doi: 10.1002/hep.28302
31 Sali S , Darvishi M , GhasemiAdl M , et al. Comparing the efficacy and safety of treating chronic hepatitis B infection during pregnancy with lamivudine, telbivudine, and tenofovir: a Meta-analysis[J]. J Clin Transl Hepatol, 2019, 7 (3): 197- 212.
32 咸建春, 周乙华. 对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》中育龄妇女抗病毒治疗期间意外妊娠推荐意见的评价[J]. 临床肝胆病杂志, 2020, 36 (2): 301- 302.
doi: 10.3969/j.issn.1001-5256.2020.02.010
XIAN Jianchun , ZHOU Yihua , et al. Comments on the recommendtions for unintended pregnancy during antiviral therapy in women of childbearing age in 2019 Chinese practice guideline for the prevention of hepatitis B virus mother-to-child transmission[J]. Journal of Clinical Hepatology, 2020, 36 (2): 301- 302.
doi: 10.3969/j.issn.1001-5256.2020.02.010
33 Gu Y , Ru T , Zhou YH , et al. Adefovir as a possible teratogen: evidence from paternal exposure[J]. Dig Liver Dis, 2014, 46 (12): 1134- 1135.
doi: 10.1016/j.dld.2014.08.035
34 Peng S , Wan Z , Liu T , et al. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus[J]. Dig Liver Dis, 2018, 50 (10): 1076- 1080.
doi: 10.1016/j.dld.2018.05.004
35 Pan CQ , Zou HB , Chen Y , et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J]. Clin Gastroenterol Hepatol, 2013, 11 (10): 1349- 1355.
doi: 10.1016/j.cgh.2013.04.026
36 Yang M , Qin Q , Fang Q , et al. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis[J]. BMC Pregnancy Childbirth, 2017, 17 (1): 303.
doi: 10.1186/s12884-017-1487-1
[1] ZHANG Yushuang, WU Juanli, GAO Han, ZHANG Yiheng, LI Tao, WANG Lei. HBV RNA status and changes after intervention in HBeAg-positive chronic hepatitis B patients with low level viremia [J]. Journal of Shandong University (Health Sciences), 2025, 63(3): 85-91.
[2] CHEN Yingjun, LIU Tonggang. Comprehensive bioinformatics analysis to identify differentially expressed genes for aberrant methylation modification in HBV-associated HCC [J]. Journal of Shandong University (Health Sciences), 2023, 61(9): 101-117.
[3] YUAN Yonggui, LI Lei, SHEN Zhongxia, CHEN Gang, WU Yigao, YUE Yingying. Prevention and control strategy for the diagnosis and treatment of psychiatric disorders during the epidemic of coronavirus disease 2019 [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 1-6.
[4] LIU Cuixiao, ZHU Xiaoyan, ZHANG Na, HUANG Pengxiang, WANG Guoyong, KANG Dianmin. Antiretrovial treatment effect and related factors of patients with human immunodeficiency virus infection and hepatitis B virus co-infection in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2020, 58(1): 60-66.
[5] BI Tao, LU Qianqian, SUN Chuandong. Effects of adenouvirus-mediated HBx on lymphocyte in vitro [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 15-20.
[6] FU Xiao-li， WANG Lei， LIU Feng. HBsAg quantitative value in different stages of hepatitis B virus infection and its correlations with serum HBV DNA and age [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 94-98.
[7] XU Hui1, WANG Yi-guo2, LIU Chang-hong2, LIU Qian2, DU Juan3. Expression of HBV and its effects on the transdifferentiation in HK-2 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 15-20.
[8] LIU Jin-rong1， WANG-Lei2， DU Wen-jun3， ZHEN Jun-hui4. Expression of IgG subclasses and its significance in hepatitis B
virus associated membranous nephropathy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 111-114.
[9] HONG Sen1， WANG Yi-guo2， LIU Chang-hong2， ZHANG Peng-ju3， LIU Qian2. Expression of recombinant HBV in the NHMC cells and its influence on cell apoptosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 34-.
[10] FAN Chun-guang1, WANG Chun-mei2, WANG Yan1, LI Li1, SUN Wen-sheng3, LIU Yu-gang1, LI Rui-feng1. Construction of an miR-122 expression vector and its inhibitory effects on proliferation of HepG2.2.15 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(10): 118-.
[11] TIAN Ming-zhong1 ，GAO Jie1， WANG Dong-qiu1， ZHU Chang-jun2. Gene therapy of endoribonucleaseⅢ-prepared siRNAs (esiRNA) library for HBV infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 42-46.
[12] GUAN Yan-yan1, YAO Yong-yuan1, WANG Gang1, SHAO Li-hua2, SAI Lin-tao1, MA Li-xian1. Influences of DMSO and dexamethasone on  HBV infection in HepCHLine4  cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(10): 65-.
[13] XUE Yan1，　WANG Lei1，　XU Wansu2
.

Domestic fluorescence quantitative PCR reagents and COBAS Amplicor assay in measuring HBVDNA: a comparison study

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(04): 62-64.
[14] ZHU Ming-ming,SUN Cheng-gang,LIU Xiao-hua,YANG Ai-xin,SUN Dan. Genetic polymorphisms of CYP17 and risks of cirrhosis or hepatocellular carcinoma in hepatitis B-infected patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 76-79.
[15] LIU You-de,WANG Lei,ZHOU Pei-jing,ZHUANG Hui. Proportional changes of HBeAg negative chronic hepatitis B and liver cirrhosis B and the HBV genotype in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 94-96.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd